ARTBIO Appoints Industry Veteran Jordi Vall-llossera as Senior Vice President and Global Head of Quality

CAMBRIDGE, Mass.; OSLO, Norway; LONDON, UK, and BASEL, Switzerland - July 17, 2023 – ARTBIO, Inc. (ARTBIO), a clinical-stage radiopharmaceutical company developing a new class of targeted alpha radioligand therapies (ART), announced the appointment of Jordi Vall-llossera as Senior Vice President and Global Head of Quality. Jordi brings over 20 years of quality assurance and operations experience in the pharmaceutical industry, including senior roles in Advanced Accelerator Applications, a Novartis Company, and Novartis. In this role, Jordi will lead all quality strategy and operational activities in support of ARTBIO’s differentiated pipeline and distributed manufacturing network.

"We are excited to welcome Jordi to the ARTBIO leadership team as we believe his vision and commitment to bringing radioligand therapies to patients aligns with our mission to redefine cancer care through a new class of alpha radioligand therapies based on Pb212,” said Emanuele Ostuni, Ph.D., Chief Executive Officer of ARTBIO. “Jordi’s extensive experience in managing quality strategy and operations, particularly in the complex radioligand therapy space, will be critical as we build out our distributed manufacturing ecosystem to be able to provide reliable and fast delivery of ARTs to the bedside. I look forward to Jordi’s impact on our organization as we scale up the ARTBIO manufacturing network.”

Jordi’s career reflects an established record of leadership in quality and supply chain processes by working closely with executive teams to reach companies’ goals. Prior to joining ARTBIO, Jordi was Head of Quality Assurance for Advanced Accelerator Applications (AAA), a Novartis company, overseeing and leading all Quality strategy and operational activities, ranging from development and clinical activities, manufacturing, testing and release activities, among other responsibilities. Prior to joining AAA in 2018, he served in several roles at Novartis, including Global Head of Supply Chain Quality Assurance, Head of Pharma Supply Chain Quality Assurance, Global Quality Process Lead within the Novartis Pharma Quality organization, and Global Quality Operations Manager for Products. He spent the first five years of his professional career as a Quality Management and Business Consultant specialized in operations and information technology at Accenture (Andersen Consulting). Jordi holds a degree in Technical Agricultural Engineering from the Polytechnic University of Catalonia and a degree in Agronomical Engineering from the University of Lleida. He has also completed a special Quality Management Program at the Escuela Organizacion Industrial in Barcelona, Spain.

"I am thrilled to join ARTBIO and be part of a dynamic company that has the potential to revolutionize the field of radioligand therapy," said Jordi. "I believe ARTBIO’s unique approach can overcome the challenges we have seen to date in the space, and I’m excited to work alongside a talented team of professionals who are passionate about making Pb212 ARTs a reality and look forward to helping guide the company’s manufacturing expansion."

About ARTBIO

ARTBIO is a clinical-stage radiopharmaceutical company redefining cancer care by creating a new class of alpha radioligand therapies (ARTs). The unique ARTBIO approach selects the optimal alpha-emitting isotope (Pb212) and tumor-specific targets to create highly targeted therapeutics. The company’s AlphaDirect^TM technology, a first-of-its-kind Pb212 isolation method, enables a distributed manufacturing approach for the reliable production and delivery of ARTs. ARTBIO is advancing three pipeline programs with lead program AB001 currently in first in human trials. ARTBIO is shaped by a long-standing scientific legacy with nearly a century of pioneering work in radiation therapy conducted at the University of Oslo and Norway’s Radium Hospital. For more information, visit www.artbio.com, and follow us on LinkedIn and Twitter.